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Hematopoietic stem cell transplant (HSCT) recipients
are profoundly immunocompromised as a result of several
factors, including underlying disease, high-dose myeloabla-
tive and immunosuppressive therapy, graft-versus-host dis-
ease (GVHD), and the treatment thereof [1,2]. Despite
improvements in patient management, infection as a conse-
quence of the abnormal immune function remains a signiﬁ-
cant cause of morbidity and mortality after HSCT [3,4].
The incidence of mycobacterial infections in HSCT recipi-
ents, although not as high as that seen in solid organ trans-
plant recipients or in patients with acquired immunodefi-
ciency syndrome (AIDS), remains higher than that in the
general population [5-7].
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ABSTRACT
Over a 20-year period, 40 nontuberculous mycobacteria (NTM) were isolated from 6259 hematopoietic stem cell
transplant (HSCT) recipients (0.64%), of which 28 were considered to have probable or definite infection (0.44%).
Only 3 of 15 lower respiratory isolates obtained by bronchoalveolar lavage (BAL) and/or biopsy; (Mycobacterium
avium complex [n = 2] and M gordonae [n = 1]) caused definite or probable lower respiratory tract disease, whereas
12 of 15 were considered to cause possible lower respiratory tract disease according to Centers for Disease Control
and Prevention definitions. The median time to diagnosis was 251 days following HSCT. All 3 patients with definite
NTM disease were successfully treated with 3 antimicrobials for several months. Twenty-three patients had
catheter-related infections, including exit site infection (n = 5), tunnel infection (n = 7), and catheter-related bac-
teremia (n = 11). All were caused by rapidly growing mycobacteria. The median time to diagnosis was 61 days fol-
lowing HSCT. All patients with catheter-related infections were successfully treated with an average of 2 antibiotics
for a median of 3 weeks for exit site infection and 6 weeks for tunnel infection and catheter-related bacteremia. Soft
tissue debridement was performed in all cases with tunnel infection. The catheter was removed in 21 of 23 patients
with catheter-related infections. Two additional patients were diagnosed, one with lymphadenitis and one with skin
lesion, due to NTM. In conclusion, NTM infections are infrequent in HSCT recipients and carry a good clinical
prognosis. In the majority of lower NTM respiratory isolates obtained by BAL, a pathogenic role could not be
established. However, lower respiratory tract disease can occur late after HSCT and should be considered if patients
fail to respond to the treatment of concomitant infections or if evidence of tissue infection or concomitant bac-
teremia is present. Therapy should be performed with 2 to 3 antimicrobials, guided by antimicrobial susceptibilities,
with additional surgical debridement in patients with tunnel infection. 
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Improvements in diagnostic laboratory methods have led
to greater and more rapid recovery of all mycobacteria, as
well as more accurate identification of the isolates [8].
Although the pathogenic role of nontuberculous mycobacte-
ria (NTM) in bloodstream and line infections is well estab-
lished [5,9-13], the signiﬁcance of NTM in respiratory sam-
ples after HSCT is frequently unclear due to the occasional
contamination of culture material or transient colonization
of the respiratory tract [8]. Moreover, clinical reports
addressing the management and prognostic implications of
NTM infections in the setting of HSCT are sparse, espe-
cially for respiratory tract infection [9,10,14]. The purpose of
this study was to define the frequency, clinical course and
outcome of NTM infections, with particular interest in the
signiﬁcance of NTM respiratory isolates.
PATIENTS AND METHODS
Study Population
Cases were identified by reviewing culture results,
patients’ records for discharge diagnoses, and databases con-
taining information on long-term follow-up of patients who
underwent HSCT at the Fred Hutchinson Cancer Research
Center between July 1977 and June 1997. The day of diag-
nosis of NTM infection was deﬁned as the day on which the
initial isolate of NTM was recovered or a diagnostic
histopathologic specimen was obtained. All patients had at
least 1 year of follow-up.
Definitions
We used the following deﬁnitions for mycobacterial dis-
ease in HSCT recipients. They were developed with investi-
gators at the Centers for Disease Control and Prevention
(unpublished data). Deﬁnite lower respiratory tract disease
was deﬁned as the presence of respiratory symptoms compati-
ble with pneumonia, pulmonary infiltrates in chest radi-
ograph, at least 1 positive culture for NTM from lower respira-
tory samples (ie, bronchoalveolar lavage [BAL], deep-tracheal
sputum), and a concomitant blood culture for NTM or histo-
logic evidence of tissue invasion by NTM. Probable lower
respiratory tract disease was deﬁned as the presence of respi-
ratory symptoms compatible with pneumonia, pulmonary
inﬁltrates in chest radiograph, and at least 1 positive culture
for NTM from lower respiratory samples (ie, BAL, deep-
expectorated sputum) but not from conﬁrmatory blood cul-
ture or histologic evidence. Possible lower respiratory tract
disease was deﬁned as the presence of respiratory symptoms
compatible with pneumonia, pulmonary inﬁltrates in chest
radiograph, positive culture for NTM from the lower respira-
tory tract (ie, BAL or deep-expectorated sputum), and either
identiﬁcation of a copathogen likely to account for the clinical
picture or improvement of respiratory symptoms and pul-
monary inﬁltrates after treatment of an alternative diagnosis
without speciﬁc treatment against NTM. 
Deﬁnite catheter-related infection was deﬁned as typical
symptoms (eg, exit site or tunnel erythema, purulence,
induration, fever, rigors, hypotension) and a positive blood
culture for NTM. Probable catheter-related infection was
deﬁned as typical symptoms (eg, exit site or tunnel erythema,
purulence, induration, fever, rigors, hypotension) and isola-
tion of NTM from the exudate or the catheter exit site, tun-
nel tissue, or catheter tip (>15 colony-forming units by the
roll-plate semiquantitative culture technique). Infections were
further categorized as exit site infection (<2 cm of inﬂamma-
tion—ie, erythema, tenderness, edema—around the exit site),
tunnel infection (>2 cm of inﬂammation from the catheter
exit site extending along the subcutaneous tract of tunneled
catheters [ie, Hickman, Broviac, or Groshong catheters]); or
catheter-related bacteremia (without exit or tunnel infection). 
Definite infections at other sites required compatible
symptoms, a positive NTM from a normally sterile site, and
histologic evidence of atypical mycobacterial tissue invasion
or a positive blood culture. Probable infections at other sites
were deﬁned as compatible symptoms and a positive NTM
from a normally sterile site but no histologic evidence of
atypical mycobacterial tissue invasion. 
Neutropenia was defined as an absolute neutrophil
count of <1000 cells/µL. It was considered a predisposing
factor for NTM infection if it occurred within 30 days
before a NTM infection. GVHD was classified as acute
(occurring within the first 100 days following HSCT) or
chronic (occurring after day 100 of HSCT) and was graded
according to previously established criteria [15,16]. Use of
corticosteroids was considered a predisposing factor for
NTM infections if used at equivalent prednisone dose of
20 mg/day or higher for 2 weeks or longer before NTM
infection was diagnosed.
Diagnostic Methods and Susceptibility Testing
Throughout the study period, all BAL and lung biopsy
specimens were tested for the presence of mycobacteria.
Specimens were processed and cultured by conventional
methods including the Bactec 12B broth radiometric culture
system and Middlebrook 7H11 agar. Mycobacteria were
identiﬁed using rapid and conventional methods, such as the
Accuprobe system for DNA probing (Gen-Probe, San
Diego, CA) and rate of growth, colonial morphology, pig-
ment production, and biochemical assays. A modiﬁcation of
the Kirby-Bauer disk diffusion test was used for susceptibil-
ity testing for rapidly growing mycobacteria, which was
performed by the microbiology laboratory at Harborview
Medical Center (Seattle, WA). This method was validated
by the micro broth dilution minimum inhibitory concentra-
tion method by correlating antibiotic zone sizes with achiev-
able minimum inhibitory concentration levels [17]. For that
correlation, samples were sent to the laboratory of Dr.
Robert J. Wallace, Jr. (Tyler, TX).
RESULTS
Incidence of Mycobacterial Infections After HSCT
Between July 1977 and June 1997, NTM isolates were
recovered from a total of 40 patients after HSCT. Of those,
15 were recovered from lung tissue and respiratory secre-
tions (Table 1). Only 3 of these patients met the criteria for
deﬁnite respiratory infection. During the same study period,
23 NTM isolates were considered to cause catheter-related
infections (including 2 cases previously reported by Navari
et al. [9]). Two additional NTM isolates were found, one
from an enlarged lymph node and the other from a skin
lesion. In total, 40 NTM infections were documented in
6259 (0.64%) HSCT recipients; 38 of the 40 occurred after
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the ﬁrst transplant (incidence 0.65%) and 2 after a second
transplant (0.5%). If one considers only deﬁnite and proba-
ble cases, the incidence was 0.45%. The prevalence among
autologous, syngeneic, and allogeneic related or unrelated
transplant recipients is shown in Figure 1. Clinical charac-
teristics of the patients with NTM isolates are summarized
in Table 1. Two additional posttransplant NTM cases previ-
ously reported by Navari et al. [9] were excluded because of
the lack of deﬁnite microbiologic diagnosis. 
Three posttransplant M tuberculosis isolates (2 of them
reported previously [9]), were recovered from pulmonary tis-
sue or respiratory secretions during the study period, result-
ing in an incidence of 0.05% (3 of 5868). Because there was
only 1 additional case, these 3 cases were not further ana-
lyzed; however, the time of onset is included in Figure 2. 
Recipients of autologous and unrelated transplants
appeared to be at higher risk than allogeneic-related trans-
plant recipients (Figure 1). However, the number of cases
did not allow a formal multivariable risk factor analysis
(Table 1). Atypical mycobacterial infections did not seem to
be associated with GVHD. For deﬁnite or probable tunnel
infections, the incidence was 11 to 2899 (0.37%) in patients
with acute grade 2-4 GVHD versus 12 to 3360 (0.35%) in
patients without GVHD. 
Nontuberculous Mycobacterial Lower Respiratory
Tract Isolates After HSCT
Only 3 of 15 NTM respiratory isolates, M avium com-
plex (MAC) (n = 2) and M gordonae (n = 1), were considered
to cause deﬁnite lower respiratory tract disease (Table 2). In
these 3 patients, the diagnosis was made a median of
251 days following HSCT (range, 240-395 days). Respira-
tory symptoms were present for a median of 7 days (range,
5-7 days) and consisted of dyspnea, cough, and scanty spu-
Table 1. Clinical Characteristics of Hematopoietic Stem Cell Transplant Recipients With Nontubercular Mycobacteria Isolates Between July 1977 and June 1997*
Definite or Probable Possible Catheter- Other Infections
Pulmonary Pulmonary Related (Definite or 
Characteristic† Infections Infections Infections Probable)
n 3 12 23 2
Sex
Male (2709) 2 8 9 1‡
Female (3550) 1 4 14 1§
Mean age, y (range) 48 (46-49) 45 (18-63) 27 (1-57) 3; 32
Underlying disease
AML, CML, or MDS (3459) 2 6 13 1
NHL or MM (712) 0 4 3 0
Others (2088) 1 2 7 1
Type of HSCT
Autologous (1176) 1 3 8 0
Related (4077) 1 7 6 2
Unrelated (1006) 1 2 9 0
Time from HSCT to 251 (240-395) 131 (46-1236) 61 (3-331) 443; 1216
diagnosis of NTM 
infection, mean d (range)
Nontubercular mycobacteria MAC, 2 MAC, 10 M abscessus, 10 MAC, 1
isolates (species, n) M gordonae, 1 M gordonae, 2 M fortuitum, 6 M gordonae, 1
M chelonae, 5
M mucogenicum, 2
Copathogens isolated|| None Aspergillus fumigatus, 3 Staphylococcus aureus, 1 None
Cytomegalovirus, 3 Candida albicans, 1
Respiratory syncytial virus, 1
Pseudomonas aeruginosa, 3
Enterococcus faecium, 1
Legionella pneumophila, 1
Staphylococcus aureus, 1
Potential predisposing factors
Neutropenia 0 0 3 (13%) 0
Acute or chronic GVHD 2 (67%) 7 (58%) 11 (47.5%) 1 (50%)
Concurrent corticosteroid 1 (33%) 5 (42%) 11 (47.5%) 1 (50%)
therapy
*AML indicates acute myeloblastic leukemia; CML, chronic myelogenous leukemia; MDS, myelodysplastic syndrome; NHL, non-Hodgkin’s lym-
phoma; MM, multiple myeloma; MAC, Mycobacterium avium complex; GVHD, graft-versus-host disease (acute: grade 2-4; chronic: clinical-extensive).
†Figures in parentheses indicate total number of patients in this category during the study period.
‡Lymphadeopathy.
§Verrucous skin lesion.
A total of 8 patients had pulmonary copathogens; some had >1 copathogen (all from BAL or lung biopsies).
tum production. Chest radiographs showed bilateral patchy
infiltrates with small bilateral pleural effusions (n = 2) or
bilateral nodular inﬁltrates (n = 1). Abnormalities on chest
computed tomographic (CT) scan were characterized by
alveolar consolidation in the affected areas and small bilat-
eral pleural effusions in 2 patients. The 2 patients with ﬁnal
diagnosis of MAC had positive sputum and BAL cultures for
this microorganism. In addition, 1 patient had a concomitant
positive blood culture and the other had an open lung
biopsy that showed noncaseating granulomas with posi-
tive acid-fast bacilli, although the culture was negative.
One patient with ﬁnal diagnosis of M gordonae had positive
BAL and lung tissue culture. Histologic examination of lung
tissue in this case showed noncaseating granulomas involv-
ing the subpleural lung tissue and the adjacent pleura.
None of the 3 patients with deﬁnite NTM respiratory
infection had been neutropenic within the 30 days before
diagnosis. One of the 3 patients had active clinical-extensive
chronic GVHD at the time of diagnosis and was receiving
treatment with corticosteroids (prednisone 60 mg/day for
the prior 2 months) for GVHD. Interestingly, none of these
3 patients had a copathogen isolated or a concomitant diag-
nosis that may have explained the respiratory symptoms.
The 2 patients with MAC respiratory infection were treated
with a newer macrolide (clarithromycin or azithromycin),
ethambutol, and either rifabutin or ciproﬂoxacin for 4 and
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Figure 1. Incidence of nontubercular mycobacteria infections after hematopoietic stem cell transplantation. Numbers above bars indicate percent-
age. There were more probable and deﬁnite infections in recipients of unrelated (P = .001) and autologous (P = .01) transplants compared with allo-
geneic related recipients. All comparisons by 2-tailed Fisher exact test.
Figure 2. Time to diagnosis of mycobacterial isolates from the day of hematopoietic stem cell transplantation for 28 patients with deﬁnite NTM
infection, 12 with possible nontubercular mycobacteria infection, and 3 with Mycobacterium tuberculosis infection.
6 months, respectively. The other patients with M gordonae
infection received isoniazid, rifampin, and pyrazinamide for
2 months followed by isoniazid and ethambutol for 10 addi-
tional months. Improvement of the radiological abnormalities
was seen after 2 weeks of therapy, but complete resolution of
infiltrates was seen only after 4 to 6 weeks of therapy. All
3 patients were successfully treated and are alive after a
median follow-up of 36 months (range, 18-54 months).
An additional 12 cases of NTM infection of the lower
respiratory tract were identiﬁed and were classiﬁed as possi-
ble lower respiratory tract disease. In these 12 patients,
NTM isolates were obtained at a median 131 days (range,
42-1236 days) after HSCT. All had respiratory symptoms,
chest radiograph findings, and isolation of NTM from
either BAL or tracheal aspirates. Respiratory symptoms
were present in all 12 patients for a median of 5.5 days
(range, 4-12 days). Different radiographic patterns were
seen on chest radiographs and CT scans, including bilateral
interstitial inﬁltrates (n = 5), bilateral nodular inﬁltrates (n = 4),
and bilateral patchy infiltrates (n = 3), some of them with
associated pleural effusions. Organisms included MAC (n = 10)
and M gordonae (n = 2). Eight patients classiﬁed as having
possible lower respiratory tract infection had evidence of
concurrent infection with 1 or 2 microorganisms (Table 1).
The other 4 patients had evidence of interstitial pneumoni-
tis in lung tissue histology, but no evidence of infectious
organisms by bacterial, fungal, or viral cultures or immuno-
histochemistry. As no infectious organism was detected,
these cases were classified as idiopathic pneumonia syn-
drome. Three of the 12 patients with possible lower respira-
tory tract infection received therapy for MAC, 2 of them for
a total of 20 days before death. At postmortem examination,
there was no evidence of acid fast bacilli or granulomas in
lung tissue, and cultures were negative for NTM (Aspergillus
fumigatus in 1 case and cytomegalovirus in the other case
had been isolated concurrently with NTM, and they were
still present in lung tissue postmortem), which suggests that
respiratory tract colonization with NTM was more likely
the case. The third patient, who also had a lung biopsy
showing acute inflammation and positive culture for
Pseudomonas aeruginosa, responded to treatment for both
NTM and P aeruginosa. Overall, 9 of the 12 patients were
not treated for NTM infection. Of them, 5 are alive without
evidence of mycobacterial infection after a median of 50
months follow-up (range, 26-90 months). Four patients died
in this group. Postmortem examination was performed in 3
of those 4 patients; it showed cytomegalovirus pneumonitis
in 1 patient and idiopathic interstitial pneumonitis in
2 patients. The fourth patient died with the clinical diagno-
sis of chronic GVHD and presumed pulmonary aspergillosis
(sputum culture positive for Aspergillus).
Nontuberculous Mycobacterial Catheter-Related
Infections After HSCT
Twenty-three HSCT recipients had NTM isolates cul-
tured from catheters, catheter sites, or blood during the
study period. All isolates belonged to the rapidly growing
mycobacteria group, M abscessus (n = 10), M fortuitum
(n = 6), M chelonae (n = 5), and M mucogenicum (n = 2).
NTM catheter-related infections were classified as
catheter exit site infection (n = 5), catheter tunnel infection
(n = 7), or catheter-related bacteremia (n = 11). All
catheters were of Hickman type; of these, 20 were placed
at the right upper chest, 2 at the left upper chest, and 1 at
the right groin. Most of the catheter-related infections
were diagnosed within the first 3 months following HSCT,
at a median time of 61 days (range, 3-331 days). In this
group, 8 patients underwent autologous HSCT, 6 patients
related HSCT, and 9 patients unrelated HSCT. Three of
the 23 HSCT recipients with catheter-related infection
were neutropenic at the time the infection was diagnosed,
and 4 more patients had been neutropenic within 15 days
before diagnosis. Acute GVHD was present in 13 of the
23 HSCT recipients with catheter-related infection (grade
I-II: n = 5; grade III-IV: n = 8).
Five patients were considered to have catheter exit site
infection and were treated with 1 or 2 antibiotics for a
median of 3 weeks (range, 2-10 weeks). In all catheter exit
site infection cases, the intravenous catheter was removed,
and no soft tissue debridement was needed. All patients
were cured at the end of antimicrobial therapy (median fol-
low-up of 8 months; range, 1-48 months). Seven patients
were treated for catheter tunnel infection with an average of
2 antibiotics (range, 1-3 antibiotics) for a median time of
Table 2. Clinical Course and Outcome of Hematopoietic Stem Cell Transplant Recipients With Pulmonary Infections*
Length of Day of X-ray Diagnostic Mycobacterial
Age, y Sex Diagnosis Symptoms Diagnosis Findings Studies Species Therapy Outcome
46 M AML 7 d 395 Bilateral patchy BAL and open M gordonae INH + RIF + PZA Cured
infiltrates and lung biopsy for 2 months,
pleural effusions then INH + EMB
for 12 months
49 F Breast 5 d 240 Bilateral patchy Sputum, BAL, MAC AZI + EMB + RBN Cured
adenocarcinoma infiltrates and and open for 6 months
pleural effusions lung biopsy
48 M CML 7 d 251 Bilateral nodular BAL and MAC CLT + EMB + CIP Cured
lung infiltrates blood culture for 4 months
*AML indicates acute myeloblastic leukemia; BAL, bronchoalveolar lavage; INH, isoniazid; RIF, rifampin; PZA, pyrazinamide; EMB, ethambutol;
MAC, Mycobacterium avium complex; AZI, azithromycin; RBN, rifabutin; CML, chronic myelogenous leukemia; CLT, clarithromycin; CIP,
ciproﬂoxacin.
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7 weeks (range, 2-12 weeks). In all these cases, the catheter
was removed and soft tissue debridement was performed. All
patients were cured with additional antimicrobial therapy
(median follow-up of 24 months; range, 18-120 months). Of
note, 2 of the 7 patients were successfully treated with soft
tissue debridement and 2 weeks of oral clarithromycin in
1 case, and 3 weeks of intravenous cefoxitin and amikacin in
the other. Both patients are alive and cured of the NTM
infection after 1 and 10 years of follow-up, respectively.
Eleven patients were treated for catheter-related bacteremia
with an average of 2 antibiotics (range, 1-3 antibiotics) for a
median time of 6 weeks (range, 2-29 weeks). Nine patients
had catheters removed and were treated successfully,
(median follow-up 12 months; range, 8-72 months). In
2 patients, classiﬁed as having probable catheter-related bac-
teremia, the catheter was not removed. One was treated
with oral ciproﬂoxacin and clarithromycin for 6 weeks, and
follow-up blood cultures were negative for NTM. This
patient died 6 weeks after the end of therapy because of
refractory non-Hodgkin’s lymphoma. The other patient
died because of severe chronic GVHD after 1 week of ther-
apy for NTM (no follow-up blood cultures were obtained).
Other Nontuberculous Mycobacterial Infections
After HSCT
Two patients were found to have NTM infection not
related to catheter infection or pulmonary disease
(Table 1). A 3-year-old girl diagnosed with acute lym-
phoblastic leukemia developed, over a 2-week period, a
tender lymphadenopathy at the left side of the neck.
Biopsy of the lymph node performed on day 443 after
HSCT showed noncaseating granulomas, and tissue cul-
ture was positive for MAC. Several sets of blood cultures
were negative for NTM. She was treated with clar-
ithromycin and rifampin for 4 months. Seven years later,
the patient is alive without leukemic relapse and without
evidence of MAC disease. The other patient is a 32-year-
old man with a diagnosis of chronic myelogenous
leukemia who, over a 3-week period, developed a verru-
cous lesion that later ulcerated, localized on the left thigh.
On day 1216 after HSCT, a skin biopsy was performed,
and tissue culture grew M chelonae. The patient was cured
after 4 weeks of monotherapy with clarithromycin. Eight
years later, the patient has no evidence of NTM disease
and no recurrence of the underlying malignancy.
Outcome in Patients With Nontuberculous
Mycobacterial Infection Before Transplant
Five additional patients had a diagnosis of NTM infec-
tion before transplant during the study period; 2 of them
were previously reported [9]. Organisms included dissemi-
nated MAC (n = 1, disseminated [blood, liver]), M fortuitum
(catheter-related, n = 2, 1 reported by Navari [9]), M absces-
sus (catheter-related, n = 1), and M kansasii (lower respira-
tory tract disease, n = 1, 1 reported by Navari [9]). All NTM
cases were definite or probable. The median time before
transplant (2 autologous, 1 syngeneic, 1 allogeneic, 1 unre-
lated donor transplant) was 5 weeks (range, 4-17 weeks). All
patients were successfully treated with combination antibi-
otic therapy and catheter removal, when catheter-related
infection was present, and had a subsequent transplant with
no recurrence of NTM disease (>1 year posttransplant).
Antibiotic treatment was continued throughout the post-
transplant period in the 2 patients with non–catheter-related
infections. In the patient with disseminated MAC infection
who received an unrelated donor transplant 17 weeks after
diagnosis, treatment was continued for the duration of
immunosuppression (12 months of ciprofloxacin, clar-
ithromycin, and clofazimine); the patient with M kansasii
pneumonia received 2 years of isoniazid and ethambutol and
1 year of rifampin following syngeneic transplantation
(reported by Navari [9]).
Susceptibility Testing Results
As a group, the rapidly growing mycobacteria were
most often susceptible to clarithromycin (17 of 18 isolates
tested), azithromycin (11 of 14), amikacin (14 of 20), and
imipenem/cilastatin (15 of 21). Variable susceptibility
results to antimicrobials were seen among the different
species of rapidly growing mycobacteria in our patient pop-
ulation (Figure 3). M abscessus isolates showed the highest
susceptibility to clarithromycin (8 of 8), whereas lower sus-
ceptibility patterns were seen for other antimicrobials: 3 of
4 for azithromycin, 6 of 9 for amikacin, and 5 of 10 for
imipenem/cilastatin. M fortuitum isolates were susceptible
to most antimicrobials tested: 6 of 6 were susceptible to
ciprofloxacin, 5 of 6 to amikacin and imipenem/cilastatin,
and 4 of 5 to clarithromycin, azithromycin, and cefoxitin.
The susceptibility patterns were less uniform for the M che-
lonae isolates: 4 of 4 were susceptible to clarithromycin and
imipenem/cilastatin; 3 of 4 were susceptible to azithro-
mycin. In our study group, only 2 cases of catheter-related
infection were due to M mucogenicum; both isolates were
susceptible to amikacin and cefoxitin, with variable results
to other antimicrobials.
DISCUSSION
In this study, we identiﬁed 40 patients with NTM infec-
tions after transplant during a 20-year period, 28 of whom
had probable or definite NTM infections (incidence of
0.5%). Deﬁnite pulmonary disease was documented in 3 of
28 patients. However, NTM were recovered from the lower
respiratory tract in 12 additional patients with pneumonia in
whom the pathogenic role remained uncertain. Outcome of
NTM disease was good with appropriate antimicrobial
treatment, which was administered for signiﬁcantly shorter
duration than that recommended in the literature. Con-
comitant surgical debridement was performed in patients
with tunnel infections.
The incidence of NTM found in this study was similar
to that reported in an earlier study from our center (approx-
imately 1%) [9], suggesting that there has been no major
increase of NTM since 1982. It is also similar to that
reported by Roy and Weisdorf [14] (University of Min-
nesota Hospital), who described 11 mycobacterial infections
in 2241 HSCT recipients (0.49%) in a 20-year retrospec-
tive review. There were 2 pulmonary and 9 extrapulmonary
infections in that study, 2 of them caused by M tuberculosis, 2
by MAC, and the other 7 by rapidly growing mycobacteria
[14]. In contrast, a report by Kurzrock et al. [10] (M.D.
Anderson Cancer Center, Texas) indicated a slightly higher
Nontuberculous Mycobacteria in HSCT
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incidence of 3 in 90 patients (3.3%). All 3 patients had pul-
monary infection caused by M tuberculosis or MAC. Addi-
tional case reports of M tuberculosis or NTM infections after
HSCT have been published without incidence ﬁgures [18-
20]. The lower rate of mycobacterial infections after HSCT
compared with that of solid organ transplantation or AIDS
[10,21] may be related, at least in part, to the recovery of the
immune function seen in HSCT recipients. Prolonged peri-
ods of extremely low CD4 counts (<10/mm3), which are
predictive for disseminated MAC in AIDS patients [21], are
rarely seen after HSCT, and immune recovery usually
occurs within 9-12 months after HSCT [22]. It is also possi-
ble that some cases of MAC bacteremia were missed because
blood cultures were not routinely screened for MAC
throughout the study period. Prospective evaluation of the
role of MAC in patients at risk for prolonged severe CD4
cytopenia is warranted.
The diagnosis of pulmonary infection with NTM in
immunocompromised hosts is often difficult given the
diverse clinical presentations and simultaneous infections
with other microorganisms. We found 15 respiratory isolates
recovered from pulmonary tissue or respiratory secretions,
and only 3 were considered to have caused deﬁnite lower res-
piratory tract disease. In these 3 cases, the diagnosis was
established by cultures from BAL and concomitant histologic
evidence of acid-fast bacilli tissue invasion or a positive blood
culture for NTM (Table 2). The 3 patients were engrafted,
and only 1 of them had chronic GVHD and was being
treated with corticosteroids. All 3 patients developed NTM
lower respiratory tract disease late in the ﬁrst year following
HSCT. Of note, the onset of pulmonary disease was signiﬁ-
cantly later than that of catheter-related infections (Table 2).
These patients were successfully treated with triple therapy
for several months. Prior reports have also shown a successful
outcome of mycobacterial infections in HSCT recipients
after appropriate therapy [14,18,23]. Of interest, 2 patients
with MAC respiratory infection were cured after a relatively
short course (4-6 months) of macrolide-containing triple reg-
imen. The optimal length of therapy for MAC lung disease
has not been established. Recommendations in the prema-
crolide era were that patients be treated for 18 to 24 months
without considering how long sputum results were negative
[5,8]. Two long-term studies of MAC lung disease found no
relapses when therapy with clarithromycin was continued for
10-12 months after negative sputum culture [11,24]. Perhaps
shorter courses of antimicrobial therapy may be effective
with the use of newer macrolide-containing triple regimens
in HSCT, especially if immunosuppression can be tapered. The
combination of a newer macrolide, ethambutol, and rifampin
or rifabutin appears to have greater in vivo activity and pro-
vide better eradication of MAC than either agent alone
[12,13]. Therefore, the potential benefit of combination
therapy is enhanced clinical activity with higher rates of
sputum conversion, higher cure rates, and fewer relapses
with shorter therapy. 
Twelve respiratory isolates were categorized as possible
lower respiratory tract infection according to recent Centers
for Disease Control and Prevention definitions. Most of
these isolates were recovered during the first 4-6 months
following HSCT (Table 1). Evidence of concomitant infec-
tion with other microorganisms or histologic evidence of
interstitial pneumonitis was present in all cases. The fact
that in this group of 9 untreated patients, 5 are alive without
evidence of NTM lower respiratory tract disease suggests
that they had lower respiratory tract colonization or conta-
mination rather than invasive disease. In the remaining 4
untreated patients who died, 3 had no evidence of NTM
disease of the lower respiratory tract or other organs at
autopsy. Treatment was not administered to these patients
because most patients were either improved or dead by the
time results became available. The most commonly isolated
species was MAC (Table 1), a common cause of colonization
in immunocompetent individuals [25]. There were no
apparent differences between patients with definite NTM
respiratory disease and those with NTM respiratory colo-
nization in terms of underlying disease, type of HSCT,
GVHD, or therapy with corticosteroids or cyclosporine,
although both groups are small. Thus, our data suggest that
lower respiratory tract colonization is common and that
recent diagnostic guidelines for lower respiratory tract dis-
Figure 3. Susceptibility testing results by modiﬁcation of the Kirby-Bauer disk diffusion test. The numbers above bars denote the number of sus-
ceptible mycobacterial isolates (numerator) out of the total isolates tested for each respective antimicrobial (denominator).
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ease by the American Thoracic Society and the American
Lung Association for NTM pulmonary disease may not be
strict enough [8]. In these guidelines, any positive culture
from lower respiratory tract secretions (eg, BAL) in combi-
nation with radiographic and clinical symptoms are suffi-
cient for the diagnosis [8]. In contrast, the present study
suggests that confirmation by biopsy or blood culture is
required if copathogens are present in the BAL.
The most frequent NTM infection in our patients was
central venous catheter-related infection. Rapidly growing
mycobacteria accounted for all those cases. The rate of
catheter-related infection caused by NTM was very low, with
only 23 cases in 6259 HSCT recipients (0.37%). All patients
with NTM catheter-related infection had tunneled Hickman
catheters. Prior publications have also reported low rates of
catheter-related infection by rapidly growing mycobacteria
in patients undergoing cancer chemotherapy or HSCT
[10,26-28]. Similar low catheter-related infection rates have
been reported in both tunneled and nontunneled long-term
catheters [10,26-28]. Most of the patients with catheter-
related infection were not neutropenic within the 30 days
before the infection (Table 1). Other than transplant type
(Figure 1), there was no apparent predisposing factor (ie,
underlying disease, GVHD, corticosteroid or cyclosporine
therapy) associated with the NTM catheter-related infection.
However, a formal multivariable risk factor analysis could
not be performed because of the small number of cases. 
Patients with catheter exit site infection were success-
fully treated with catheter removal and an average of
2 antibiotics administered for 2-4 weeks. Most antimicrobial
regimens for catheter tunnel infection or catheter-related
bacteremia consisted of an initial phase with 2 antimicro-
bials administered intravenously (eg, amikacin, imipenem/
cilastatin, cefoxitin, tobramycin) for 2-4 weeks, followed by
2 antimicrobials administered orally (eg, clarithromycin,
ciproﬂoxacin, doxycycline) for 4-6 weeks. All patients with
tunnel infection underwent surgical debridement of the soft
tissue around the tunnel tract. There were no fatalities
directly related to NTM catheter-related infection. All
patients were successfully treated with appropriate antibi-
otics and, if needed, surgical therapy. Similar good outcomes
have been reported by others [9,10,14].
Rapidly growing mycobacteria are resistant to the anti-
tuberculous agents, but they are variably susceptible to a
number of traditional antibacterial agents. Most of our iso-
lates were sensitive to clarithromycin, azithromycin,
amikacin, and imipenem/cilastatin. Among the different iso-
lates that were tested, M fortuitum strains had the highest
susceptibility to most antimicrobials, followed by M abscessus
and M chelonae (Figure 3). Two strains of M mucogenicum
were susceptible to amikacin and cefoxitin and showed vari-
able susceptibilities to other antimicrobials. Because of vari-
able antimicrobial susceptibility among species and even
within species [29,30], susceptibility testing of significant
rapidly growing mycobacteria isolates should always be per-
formed for adequate selection of antimicrobial therapy.
In conclusion, the incidence of NTM infection in
HSCT recipients, although higher than that in the general
population, seems to be lower than that in patients with
solid organ transplantation or with AIDS not treated with
potent antiretroviral therapy. The diagnosis of NTM respi-
ratory infection is often difﬁcult because of nonspeciﬁc clin-
ical presentations and the presence of copathogens. Our
data suggest that in the absence of histologic signs of tissue
invasion or positive blood cultures and in the presence of
copathogens, NTM respiratory isolates in HSCT recipients
often represent lower respiratory tract colonization. Never-
theless, lower respiratory tract disease does occur late after
transplantation, and the outcome is usually good with the
combination regimens that include new macrolides for sev-
eral months. Six months of therapy is likely to be sufﬁcient,
provided that there is adequate clinical response; conversion
of positive sputum cultures should also be documented if
they were present at onset [8]. Catheter-related infection
was the most common manifestation of NTM infection
after HSCT in this study, and it was always caused by
rapidly growing mycobacteria. In catheter-related infection
with NTM, removal of the vascular catheter is required for
a cure. Likewise, in catheter tunnel infection, surgical
debridement of the soft tissues around the catheter tract is
necessary for optimal management. Antimicrobial therapy
for rapidly growing mycobacteria should always be given as
combination therapy. Based on our data, an initial empiric
regimen of clarithromycin plus imipenem/cilastatin and/or
amikacin is likely to provide adequate antimicrobial cover-
age until results of NTM susceptibility testing are available.
Shorter treatment courses than suggested in the literature
may be adequate in the HSCT setting, ie, 4 weeks for exit
site infections without bacteremia and 6-8 weeks for tunnel
infections or bacteremia. The outcome of catheter-related
infection due to NTM is excellent when the vascular
catheter is removed and the appropriate antimicrobials are
administered. Finally, our experience suggests that patients
with pretransplantation NTM infections can be trans-
planted without posttransplantation relapse of infection.
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